Immunomicelles for advancing personalized therapy.
Personalized medicine, which ultimately seeks to afford tailored therapeutic regimens for individual patients, is quickly emerging as a new paradigm in the diagnosis and treatment of diseases. The idea of casting aside generic treatments in favor of patient-centric therapies has become feasible owing to advances in nanotechnology and drug delivery coupled with an enhanced knowledge of genomics and an understanding of disease at the molecular level. This review highlights polymeric immunomicelles as a class of nanocarriers that have the potential to combine diagnosis, targeted drug therapy, as well as imaging and monitoring of therapeutic response, to render a personalized approach to the management of disease. Smart multi-functional immunomicelles, as the next generation of nanocarriers, are poised for facilitating personalized cancer treatment. This review provides an assessment of immunomicelles as tools for advancing personalized therapy of diseases, with cancer being the major focus.
Center for Pharmaceutical Biotechnology and Nanomedicine, Northeastern University, Boston, MA 02115, USA.
Rupa R
RR
Sawant
Aditi M
AM
Jhaveri
Vladimir P
VP
Torchilin
D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage; D004337:Drug Carriers / Q000008:administration & dosage*; D006801:Humans; D008823:Micelles; D050997:Nanomedicine; D009369:Neoplasms / Q000188:drug therapy; D058226:Plaque, Atherosclerotic / Q000175:diagnosis; D011108:Polymers / Q000008:administration & dosage; D057285:Precision Medicine; D034741:RNA, Small Interfering / Q000008:administration & dosage
D000970:Antineoplastic Agents; D004337:Drug Carriers; D008823:Micelles; D011108:Polymers; D034741:RNA, Small Interfering